AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30849082 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/3R BPND measured by PET scanning
Number of subjects: 26
Study 30849082 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour oral glucose tolerance test to measure DI by OMM
Number of subjects: 26
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI (hs-cTnI) testing
Number of subjects: 919
Study 30849383 — intervention group
Group type: COMPARATOR
Intervention: Cardiologists' classification of cTnI orders
Number of subjects: 919
Study 30849383 — intervention group
Group type: COMPARATOR
Intervention: Cardiologists' classification of hs-cTnI orders
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for type 1 myocardial infarction
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for type 2 myocardial infarction
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cTnI testing for myocardial injury
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for type 1 myocardial infarction
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for type 2 myocardial infarction
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cTnI testing for myocardial injury
Number of subjects: 919
Study 30849383 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance in appropriateness adjudication forms
Number of subjects: 919
Study 30849758 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 362
Study 30849758 — intervention group
Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 362
Study 30850011 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tamoxifen
Number of subjects: 21
Study 30850011 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tamoxifen
Number of subjects: 21
Study 30850011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both dosages)
Number of subjects: 21
Study 30850297 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant II/IIs endograft in conjunction with Heli-FX EndoAnchor implants (ESAR)
Number of subjects: 70
Study 30850312 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-child visits screening
Number of subjects: 3475
Study 30850312 — intervention group
Group type: COMPARATOR
Intervention: Acute-care visits screening
Number of subjects: 3475
Study 30850312 — intervention group
Group type: COMPARATOR
Intervention: Acute-care visits only
Number of subjects: 3475
Study 30850381 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus R-CHOP
Number of subjects: 56
Study 30850381 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus G-CHOP
Number of subjects: 56
Study 30850381 — intervention group
Group type: COMPARATOR
Intervention: G-CHOP (control)
Number of subjects: 56
Study 30850416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercisers (11 men and 1 woman)
Number of subjects: 29
Study 30850416 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (14 men and 3 women)
Number of subjects: 29
Study 30850562 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin and oxaliplatin (OHP) administered intravenously at doses of 7.5 mg/m², with radiotherapy delivered at a daily fraction of 2.0 Gy to a total dose of 60.0 Gy over 6 weeks.
Number of subjects: 37
Study 30851070 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1377
Study 30851070 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 1377
Study 30851070 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1377
Study 30851221 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with BD
Number of subjects: 108
Study 30851221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with BD
Number of subjects: 108
Study 30851221 — intervention group
Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 108
Study 30851221 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 108
Study 30852126 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 3.73 ± 1.72 mg) for 6 weeks
Number of subjects: 42
Study 30852126 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy matched controls)
Number of subjects: 42
Study 30852540 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth-based 12-week physical activity programme using a Fitbit activity tracker, remotely prescribed and monitored by a physiotherapist.
Number of subjects: 60
Study 30852546 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) evaluation using offline and online technologies including proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry, gas chromatography mass spectroscopy, and comprehensive two-dimensional gas chromatography-mass spectrometry.
Number of subjects: 0
Study 30852546 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I, and blood eosinophil levels.
Number of subjects: 0
Study 30852561 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (CryoTBB)
Number of subjects: 61
Study 30852587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong HIV
Number of subjects: 66
Study 30852587 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 66
Study 30852604 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 4687
Study 30852604 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4687
Study 30852604 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 18-25
Number of subjects: 4687
Study 30852767 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal pain severity assessed by PAGI-SYM
Number of subjects: 346
Study 30852767 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased upper abdominal pain severity
Number of subjects: 346
Study 30852767 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 346
Study 30852767 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain prevalence
Number of subjects: 346
Study 30852966 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum netrin-1 levels
Number of subjects: 3346
Study 30852966 — intervention group
Group type: COMPARATOR
Intervention: Baseline National Institutes of Health Stroke Scale score and other potential confounders
Number of subjects: 3346
Study 30853049 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Decision Support System (CDSS) for OSA detection
Number of subjects: 2535
Study 30853195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric weight management programs
Number of subjects: 6454
Study 30853195 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥12 years), greater severity of obesity, and Hispanic race/ethnicity
Number of subjects: 6454
Study 30853195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-percentage point decrease in %BMIp95
Number of subjects: 6454
Study 30853233 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure
Number of subjects: 793
Study 30853233 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak mean arterial pressure
Number of subjects: 793
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in never injectors
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID not on OAT
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID on OAT
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in ongoing drug users (with or without OAT)
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in ongoing drug users
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in never injectors (per protocol analysis)
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID not on OAT (per protocol analysis)
Number of subjects: 1752
Study 30853642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID on OAT (per protocol analysis)
Number of subjects: 1752
Study 30854456 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectroscopic MRI (sMRI) integrated with standard imaging for radiation therapy planning
Number of subjects: 18
Study 30855220 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplant (UTx)
Number of subjects: 19
Study 30855519 — intervention group
Group type: EXPERIMENTAL
Intervention: WAGR subjects with BDNF gene deletion
Number of subjects: 0
Study 30855519 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous Bdnf knockout rats
Number of subjects: 0
Study 30855742 — intervention group
Group type: EXPERIMENTAL
Intervention: EVD survivors
Number of subjects: 966
Study 30857495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 386
Study 30857528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation Seeking Scale for Young Children
Number of subjects: 423
Study 30857532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural glycemic variability (mean daily δ blood glucose during the first 2 days after TAVI, median value 4.3 mmol/l)
Number of subjects: 160
Study 30857780 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with a different antiviral regimen
Number of subjects: 0
Study 30857849 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 834
Study 30857849 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHD (complex CHD types)
Number of subjects: 834
Study 30857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously)
Number of subjects: 57
Study 30857956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 57
Study 30858085 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLX101 with standard neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 32
Study 30858218 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM265 at 400 mg
Number of subjects: 0
Study 30858218 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30858739 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin (pegIFN-α2a/RBV) for 48 weeks
Number of subjects: 32
Study 30858739 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability of the regimen
Number of subjects: 32
Study 30858826 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30858899 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational workshop (two-day workshop with short conferences, group sharing, and role playing activities)
Number of subjects: 7
Study 30858985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein supplementation (5.2 g daily for 6 weeks)
Number of subjects: 24
Study 30858985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30858986 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless monitoring system
Number of subjects: 250
Study 30858986 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study 30859371 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care measurement of purines (adenosine, inosine, hypoxanthine) using SMARTCap biosensor in stroke patients
Number of subjects: 128
Study 30859371 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care measurement of purines (adenosine, inosine, hypoxanthine) using SMARTCap biosensor in stroke patients after 24 hours
Number of subjects: 128
Study 30859371 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of purine levels with volume of affected brain tissue
Number of subjects: 128
Study 30859424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) sampling using dual tracer method
Number of subjects: 10
Study 30859424 — intervention group
Group type: COMPARATOR
Intervention: Single agent blue dye injection
Number of subjects: 10
Study 30859504 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized trials of BP medications
Number of subjects: 10
Study 30859504 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazides
Number of subjects: 10
Study 30859504 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system-blocking agents
Number of subjects: 10
Study 30859504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thiazide and beta-blocker
Number of subjects: 10
Study 30859504 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of three classes of BP medications
Number of subjects: 10
Study 30859546 — intervention group
Group type: COMPARATOR
Intervention: Women without avulsions
Number of subjects: 189
Study 30859546 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with avulsions
Number of subjects: 189
Study 30859546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anterior compartment stage ≥III
Number of subjects: 189
Study 30859546 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative symptom score
Number of subjects: 189
Study 30860013 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction (PCR) testing
Number of subjects: 0
Study 30860484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet app for the Simplified Gestational Age Score (T-SGAS) used by auxiliary nurse midwives to estimate GA status of newborns.
Number of subjects: 0
Study 30860484 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SGAS app
Number of subjects: 0
Study 30860496 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined composition CD19 CAR T cells
Number of subjects: 43
Study 30860858 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma controller medication adherence
Number of subjects: 0
Study 30860858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute healthcare use
Number of subjects: 0
Study 30860945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once per day plus capecitabine 750 mg/m²
Number of subjects: 49
Study 30861475 — intervention group
Group type: EXPERIMENTAL
Intervention: Better mental health (higher MHI-5 scores)
Number of subjects: 668
Study 30861475 — intervention group
Group type: COMPARATOR
Intervention: More mental health problems (lower MHI-5 scores)
Number of subjects: 668
Study 30862609 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy (platinum/pemetrexed)
Number of subjects: 1
Study 30862646 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide/dexamethasone
Number of subjects: 45
Study 30862646 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (5 mg/kg, 10 mg/kg, or 20 mg/kg)
Number of subjects: 45
Study 30862646 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (10 mg/kg)
Number of subjects: 45
Study 30862645 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 82
Study 30862650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled insulin pen caps
Number of subjects: 75
Study 30862650 — intervention group
Group type: EXPERIMENTAL
Intervention: Most adherent tertile
Number of subjects: 75
Study 30863020 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (educational program for psychiatrists, collaborative care program for patients and relatives, reminder system using a medication reminder application)
Number of subjects: 400
Study 30863020 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 400
Study 30863043 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients during acute exacerbation
Number of subjects: 181
Study 30863141 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane (up to 6 mL)
Number of subjects: 96
Study 30863141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 96
Study 30863141 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment effect of methoxyflurane vs placebo
Number of subjects: 96
Study 30863297 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 22
Study 30863297 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous TBS (cTBS)
Number of subjects: 22
Study 30863450 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSC + PE
Number of subjects: 110
Study 30863450 — intervention group
Group type: COMPARATOR
Intervention: Single treatment (Control)
Number of subjects: 110
Study 30863936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 1140
Study 30863936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1140
Study 30864114 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 7
Study 30864887 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30865002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Index-3 score higher than seven points
Number of subjects: 0
Study 30865002 — intervention group
Group type: COMPARATOR
Intervention: Lack of PONV prophylaxis
Number of subjects: 0
Study 30865002 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of opioids
Number of subjects: 0
Study 30865002 — intervention group
Group type: COMPARATOR
Intervention: Patient age
Number of subjects: 0
Study 30865002 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 30865003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative FiO2 of 80%
Number of subjects: 5056
Study 30865003 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative FiO2 of 30%
Number of subjects: 5056
Study 30865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0
Study 30865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study 30865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle interventions
Number of subjects: 0
Study 30865059 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation strategies
Number of subjects: 0
Study 30865223 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapies (MBRT)
Number of subjects: 2579
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure medications (including ACE-Is/ARBs, β-blockers, MRAs, digoxin, ivabradine, diuretics)
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro B-type natriuretic peptide levels
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of atrial fibrillation
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of anaemia
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of HFmrEF
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of HFpEF
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 123
Study 30865367 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 123
Study 30865549 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Number of subjects: 118
Study 30865549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 118
Study 30865772 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided lumbar epidural needle insertion
Number of subjects: 22
Study 30865842 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30866001 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-facing family health history (FHH)-based risk assessment platform
Number of subjects: 2514
Study 30866104 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 19
Study 30866104 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 19
Study 30866621 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise integrated with education
Number of subjects: 44
Study 30866621 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 44
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: nHDL <100 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: nHDL 100-129 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: nHDL ≥130 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL <70 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL 70-99 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL ≥100 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride <84 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride 84-149 mg/dL
Number of subjects: 1843
Study 30866657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride ≥150 mg/dL
Number of subjects: 1843
Study 30866676 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance model
Number of subjects: 13
Study 30866676 — intervention group
Group type: COMPARATOR
Intervention: Non-ceding site
Number of subjects: 13